Literature DB >> 29490071

Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results.

Angela R Bradbury1, Linda J Patrick-Miller2, Brian L Egleston3, Michael J Hall3, Susan M Domchek1, Mary B Daly3, Pamela Ganschow4, Generosa Grana5, Olufunmilayo I Olopade2, Dominique Fetzer1, Amanda Brandt1, Rachelle Chambers2, Dana F Clark5, Andrea Forman3, Rikki Gaber4, Cassandra Gulden2, Janice Horte5, Jessica M Long1, Terra Lucas4, Shreshtha Madaan2, Kristin Mattie5, Danielle McKenna1, Susan Montgomery3, Sarah Nielsen2, Jacquelyn Powers1, Kim Rainey3, Christina Rybak3, Michelle Savage3, Christina Seelaus4, Jessica Stoll2, Jill E Stopfer1, Xinxin Shirley Yao5.   

Abstract

Background: Germline genetic testing is standard practice in oncology. Outcomes of telephone disclosure of a wide range of cancer genetic test results, including multigene panel testing (MGPT) are unknown.
Methods: Patients undergoing cancer genetic testing were recruited to a multicenter, randomized, noninferiority trial (NCT01736345) comparing telephone disclosure (TD) of genetic test results with usual care, in-person disclosure (IPD) after tiered-binned in-person pretest counseling. Primary noninferiority outcomes included change in knowledge, state anxiety, and general anxiety. Secondary outcomes included cancer-specific distress, depression, uncertainty, satisfaction, and screening and risk-reducing surgery intentions. To declare noninferiority, we calculated the 98.3% one-sided confidence interval of the standardized effect; t tests were used for secondary subgroup analyses. Only noninferiority tests were one-sided, others were two-sided.
Results: A total of 1178 patients enrolled in the study. Two hundred eight (17.7%) participants declined random assignment due to a preference for in-person disclosure; 473 participants were randomly assigned to TD and 497 to IPD; 291 (30.0%) had MGPT. TD was noninferior to IPD for general and state anxiety and all secondary outcomes immediately postdisclosure. TD did not meet the noninferiority threshold for knowledge in the primary analysis, but it did meet the threshold in the multiple imputation analysis. In secondary analyses, there were no statistically significant differences between arms in screening and risk-reducing surgery intentions, and no statistically significant differences in outcomes by arm among those who had MGPT. In subgroup analyses, patients with a positive result had statistically significantly greater decreases in general anxiety with telephone disclosure (TD -0.37 vs IPD +0.87, P = .02). Conclusions: Even in the era of multigene panel testing, these data suggest that telephone disclosure of cancer genetic test results is as an alternative to in-person disclosure for interested patients after in-person pretest counseling with a genetic counselor.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29490071      PMCID: PMC6136932          DOI: 10.1093/jnci/djy015

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  48 in total

1.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

2.  A power primer.

Authors:  J Cohen
Journal:  Psychol Bull       Date:  1992-07       Impact factor: 17.737

3.  A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire.

Authors:  David Cella; Chanita Hughes; Amy Peterman; Chih-Hung Chang; Beth N Peshkin; Marc D Schwartz; Lari Wenzel; Amy Lemke; Alfred C Marcus; Caryn Lerman
Journal:  Health Psychol       Date:  2002-11       Impact factor: 4.267

4.  Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007.

Authors:  Gordon F Schwartz; Kevin S Hughes; Henry T Lynch; Carol J Fabian; Ian S Fentiman; Mark E Robson; Susan M Domchek; Lynn C Hartmann; Roland Holland; David J Winchester
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

5.  Genetic counseling for families with inherited susceptibility to breast and ovarian cancer.

Authors:  B B Biesecker; M Boehnke; K Calzone; D S Markel; J E Garber; F S Collins; B L Weber
Journal:  JAMA       Date:  1993-04-21       Impact factor: 56.272

6.  Germline Mutations in Predisposition Genes in Pediatric Cancer.

Authors:  Jinghui Zhang; Michael F Walsh; Gang Wu; Kim E Nichols; Michael N Edmonson; Tanja A Gruber; John Easton; Dale Hedges; Xiaotu Ma; Xin Zhou; Donald A Yergeau; Mark R Wilkinson; Bhavin Vadodaria; Xiang Chen; Rose B McGee; Stacy Hines-Dowell; Regina Nuccio; Emily Quinn; Sheila A Shurtleff; Michael Rusch; Aman Patel; Jared B Becksfort; Shuoguo Wang; Meaghann S Weaver; Li Ding; Elaine R Mardis; Richard K Wilson; Amar Gajjar; David W Ellison; Alberto S Pappo; Ching-Hon Pui; James R Downing
Journal:  N Engl J Med       Date:  2015-11-18       Impact factor: 91.245

7.  Patients' understanding of and responses to multiplex genetic susceptibility test results.

Authors:  Kimberly A Kaphingst; Colleen M McBride; Christopher Wade; Sharon Hensley Alford; Robert Reid; Eric Larson; Andreas D Baxevanis; Lawrence C Brody
Journal:  Genet Med       Date:  2012-07       Impact factor: 8.822

8.  Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility.

Authors:  Angela R Bradbury; Linda Patrick-Miller; Jessica Long; Jacquelyn Powers; Jill Stopfer; Andrea Forman; Christina Rybak; Kristin Mattie; Amanda Brandt; Rachelle Chambers; Wendy K Chung; Jane Churpek; Mary B Daly; Laura Digiovanni; Dana Farengo-Clark; Dominique Fetzer; Pamela Ganschow; Generosa Grana; Cassandra Gulden; Michael Hall; Lynne Kohler; Kara Maxwell; Shana Merrill; Susan Montgomery; Rebecca Mueller; Sarah Nielsen; Olufunmilayo Olopade; Kimberly Rainey; Christina Seelaus; Katherine L Nathanson; Susan M Domchek
Journal:  Genet Med       Date:  2014-10-09       Impact factor: 8.822

Review 9.  Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing.

Authors:  Yuan Xue; Arunkanth Ankala; William R Wilcox; Madhuri R Hegde
Journal:  Genet Med       Date:  2014-09-18       Impact factor: 8.822

10.  Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.

Authors:  Holly LaDuca; A J Stuenkel; Jill S Dolinsky; Steven Keiles; Stephany Tandy; Tina Pesaran; Elaine Chen; Chia-Ling Gau; Erika Palmaer; Kamelia Shoaepour; Divya Shah; Virginia Speare; Stephanie Gandomi; Elizabeth Chao
Journal:  Genet Med       Date:  2014-04-24       Impact factor: 8.822

View more
  10 in total

1.  GeneMatch: A novel recruitment registry using at-home APOE genotyping to enhance referrals to Alzheimer's prevention studies.

Authors:  Jessica B Langbaum; Jason Karlawish; J Scott Roberts; Elisabeth M Wood; Angela Bradbury; Nellie High; Trisha L Walsh; David Gordon; Raj Aggarwal; Peter Davis; Carter Stowell; Lane Trisko; Carolyn M Langlois; Eric M Reiman; Pierre N Tariot
Journal:  Alzheimers Dement       Date:  2019-02-13       Impact factor: 21.566

2.  Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study.

Authors:  Nina Beri; Linda J Patrick-Miller; Brian L Egleston; Michael J Hall; Susan M Domchek; Mary B Daly; Pamela Ganschow; Generosa Grana; Olufunmilayo I Olopade; Dominique Fetzer; Amanda Brandt; Rachelle Chambers; Dana F Clark; Andrea Forman; Rikki Gaber; Cassandra Gulden; Janice Horte; Jessica Long; Terra Lucas; Shreshtha Madaan; Kristin Mattie; Danielle McKenna; Susan Montgomery; Sarah Nielsen; Jacquelyn Powers; Kim Rainey; Christina Rybak; Michelle Savage; Christina Seelaus; Jessica Stoll; Jill E Stopfer; Xinxin Shirley Yao; Angela R Bradbury
Journal:  Clin Genet       Date:  2018-12-07       Impact factor: 4.438

3.  Do research participants share genomic screening results with family members?

Authors:  Julia Wynn; Hila Milo Rasouly; Tania Vasquez-Loarte; Akilan M Saami; Robyn Weiss; Sonja I Ziniel; Paul S Appelbaum; Ellen Wright Clayton; Kurt D Christensen; David Fasel; Robert C Green; Heather S Hain; Margaret Harr; Christin Hoell; Iftikhar J Kullo; Kathleen A Leppig; Melanie F Myers; Joel E Pacyna; Emma F Perez; Cynthia A Prows; Alanna Kulchak Rahm; Gemme Campbell-Salome; Richard R Sharp; Maureen E Smith; Georgia L Wiesner; Janet L Williams; Carrie L Blout Zawatsky; Ali G Gharavi; Wendy K Chung; Ingrid A Holm
Journal:  J Genet Couns       Date:  2021-10-19       Impact factor: 2.717

4.  Use and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study.

Authors:  Michael J Hall; Linda J Patrick-Miller; Brian L Egleston; Susan M Domchek; Mary B Daly; Pamela Ganschow; Generosa Grana; Olufunmilayo I Olopade; Dominique Fetzer; Amanda Brandt; Rachelle Chambers; Dana F Clark; Andrea Forman; Rikki Gaber; Cassandra Gulden; Janice Horte; Jessica M Long; Terra Lucas; Shreshtha Madaan; Kristin Mattie; Danielle McKenna; Susan Montgomery; Sarah Nielsen; Jacquelyn Powers; Kim Rainey; Christina Rybak; Michelle Savage; Christina Seelaus; Jessica Stoll; Jill E Stopfer; Xinxin Shirley Yao; Angela R Bradbury
Journal:  JCO Precis Oncol       Date:  2018-12-18

5.  Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer.

Authors:  Rachel A Pozzar; Fangxin Hong; Niya Xiong; Jill E Stopfer; Manan M Nayak; Meghan Underhill-Blazey
Journal:  Fam Cancer       Date:  2021-03-10       Impact factor: 2.375

6.  Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.

Authors:  Jennifer L Caswell-Jin; Anjali D Zimmer; Will Stedden; Kerry E Kingham; Alicia Y Zhou; Allison W Kurian
Journal:  J Natl Cancer Inst       Date:  2019-01-01       Impact factor: 13.506

Review 7.  Helping Patients Understand and Cope with BRCA Mutations.

Authors:  Sukh Makhnoon; Banu Arun; Isabelle Bedrosian
Journal:  Curr Oncol Rep       Date:  2022-03-18       Impact factor: 5.945

8.  Clinical genetic counselor experience in the adoption of telehealth in the United States and Canada during the COVID-19 pandemic.

Authors:  Daria Ma; Priyanka R Ahimaz; James M Mirocha; Lola Cook; Jessica L Giordano; Pooja Mohan; Stephanie A Cohen
Journal:  J Genet Couns       Date:  2021-11-10       Impact factor: 2.717

9.  Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.

Authors:  Allison W Kurian; Kevin C Ward; Paul Abrahamse; Irina Bondarenko; Ann S Hamilton; Dennis Deapen; Monica Morrow; Jonathan S Berek; Timothy P Hofer; Steven J Katz
Journal:  J Clin Oncol       Date:  2021-02-09       Impact factor: 44.544

10.  Randomized study of remote telehealth genetic services versus usual care in oncology practices without genetic counselors.

Authors:  Cara N Cacioppo; Brian L Egleston; Dominique Fetzer; Colleen Burke Sands; Syeda A Raza; Neeraja Reddy Malleda; Elisabeth McCarty Wood; India Rittenburg; Julianne Childs; David Cho; Martha Hosford; Tina Khair; Jamil Khatri; Lydia Komarnicky; Trina Poretta; Fahd Rahman; Satish Shah; Linda J Patrick-Miller; Susan M Domchek; Angela R Bradbury
Journal:  Cancer Med       Date:  2021-06-08       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.